Ginkgo biloba for intermittent claudication

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Nicolaï, Saskia P A ^a   Kruidenier, Lotte M ^a   Bendermacher, Bianca L W ^a   Prins, Martin H ^b   Teijink, Joep A W ^a  

^a Sittard Geleen Heerlen   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLAVONOID; GINKGO BILOBA EXTRACT; GINKGOLIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAFTIDROFURYL; PENTOXIFYLLINE; PLACEBO; THROMBOCYTE ACTIVATING FACTOR;

ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ANTIOXIDANT ACTIVITY; ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DRUG EFFICACY; EFFECT SIZE; EMBASE; ENERGY EXPENDITURE; FILM COATING; FOLLOW UP; FUNCTIONAL DISEASE; GASTROINTESTINAL SYMPTOM; GINKGO BILOBA; GLUCOSE METABOLISM; HEADACHE; HEMATURIA; HUMAN; INFORMATION RETRIEVAL; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LEG PAIN; MEDLINE; METHODOLOGY; NAUSEA; PRESCRIPTION; PUBLISHING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SAMPLE SIZE; SHORT FORM 36; SKIN ALLERGY; SMOKING CESSATION; SYSTEMATIC REVIEW; TABLET; THROMBOCYTE AGGREGATION; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WALKING;

EID: 70349145491     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006888.pub2     Document Type: Review

References (54)

1. Bauer U. 6-Month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insuffiency. Arzneimittel-Forschung 1984;34(6):716-720 (Pubitemid 14076385)
2. Blume J, Kieser M, Holscher U. [Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication]. Vasa 1996;25(3): 265-274
3. Blume J, Kieser M, Hölscher U. Ginkgo-special-extract EGb 761 in peripheral arterial occlusive diseases stage IIb according to Fontaine. Fortschritte der Medizin 1998;116(35-6):36-37
4. Bulling B, von Bary S. Treatment of chronic peripheral occlusive disease with physical training and ginkgo biloba extraxt 761 [Behandlung der chronischen peripheren arteriellen Verschlusskrankheit met physikalischem Training und Ginkgo-biloba-Extrakt 761, Ergebnisse einer placebokontrollierten Doppelblindstudie]. Medizinische Welt 1991;42(8):702-708
5. Diehm C, Heinrich F, Mörl H. Placebo-controlled, multicentre, randomised, double-blind pilot study examining the effectiveness of Ginkgo biloba extract EGb 761® in patients with Fontaine stage IIb peripheral aterial disease [Placebokontrollierte, multizentrische, randomisierte, doppelblinde Pilotstudie zur Prüfung der Wirksamkeit des Ginkgo-biloba-Extraktes EGb 761® bei Patienten mit peripherer arterieller Verschlusskrankheit im Stadium IIb nach Fontaine]. Internal report. Dr. Willmar Schwabe GmbH & Co. 1990.
6. Drabaek H, Petersen JR, Winberg N, Hansen KF, Mehlsen J. The effect of Ginkgo biloba extract in patients with intermittent claudication. Ugeskrift for Laeger 1996;158(27):3928-3931 (Pubitemid 26227988)
7. Gardner CD, Taylor-Piliae RE, Kiazand A, Nicholus J, Rigby AJ, Farquhar JW. Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral arterial disease. Journal of Cardiopulmonary Rehabilitation and Prevention 2008;28(4):258-265
8. Mouren X, Caillard P, Schwartz F. Study of the antiischemic action of EGb 761 in the treatment of peripheral arterial occlusive disease by TcPO2 determination. Angiology 1994;45(6):413-417 (Pubitemid 24179171)
9. Natali J. Protocol for a study comparing Ginkgo biloba extract and placebo in patients with arteriopathy of the lower extremities [Protocole d́tude de l'extrait de Ginkgo biloba face au placebo dans l'artéropathie des membres inférieurs]. Internal Study Report, Ipsen, Paris 1985.
10. Peters H, Kieser M, Holscher U. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication- -a placebo-controlled, double-blind multicenter trial. Vasa 1998;27 (2):106-110 (Pubitemid 28232161)
11. SalzH. The effectiveness of a Ginkgobiloba preparation in arterial ischemic diseases of the leg. Controlled double-blind cross-over study. Therapie der Gegenwart 1980;119(11):1345-1356
12. Schoop W, Breddin K, Diehm C, Grub J, Held K, Horsch S, et al. Clinical test with ginkgo biloba EGb 761 extract for patients with peripheral arterial occlusive disease stage IIb fontaine in comparison with placebo [Klinische prufung mit ginkgo biloba-spezialextrakt EGb 761 bei patienten mit peripherer arterieller verschlusskrankheit im stadium IIb nach fontaine im vergleich zu placebo]. Vasa 1997; 26:160 (P15).
13. Thomson GJL, Vohra RK, Carr MH, Walker MG. A clinical trial of Gingkco Biloba Extract in patients with intermittent claudication. International Angiology 1990;9(2):75-78
14. Wang JZ. Supervised exercise training combined with ginkgo biloba treatment for patients with peripheral arterial disease. Clinical Reha- bilitation 2007;21(7):579-586
15. Ambrosi C, Bourde C. A new therapeutic intervention arteriopathies of the lower extermities: Tanakan. Clinical trial and study of liquid crystals [Nouveauté thèrapeutique médicinale dans les artériopathies des membres d'inferieur: Tanakan. Essai clinique et étude par les cristaux liquides]. Gazette médicale de France 1975;82:628-633
16. Baitsch G. Treatment of obliterative arterial disease in diabetics (Fontaine's stage IV) with moist gangrene. Clinical Trials Journal 1986;23(1):11-19 (Pubitemid 16120087)
17. Berndt ED, Kramer M. Medicational therapy of peripheral artreial occlusive disease in stage IIb [Medikamentöse Therapie der peripheren arteriellen Verschlusskrankheit im Staium IIb]. die Therapiewoche 1986;37:2815-2819
18. Bohmer D, Kalinski S, Michaelis P, Szogy A. Efficacy and tolerance of Ginkgo biloba extract compared to that of pentoxifylline in the treatment of patients suffering from peripheral chronic arterial occlusive disease. Hers Kreislauf 1988;20(1):5-8. (Pubitemid 18028999)
19. Courbier R, Jausseran JM, Reggi M. Double blind, cross over trial of Tanakan in arteriopathies of the lower extremities [Étude à double insu croisée du Tanakan dans les arteriopathies des membres inférieurs]. Méditerranée Médicale 1977;126:61-64
20. Frileux C, Copé R. Concentrated extract of Ginkgo biloba in peripheral vascular disorders [L'extrait concentré de Ginkgo biloba* dans les troubles vasculaires périphériques]. Cahiers d'Artériologie de Royat 1975;3:117-122
21. Garzya G, Picari M. Treatment of blood vessel devices with a new substance mining: the Tanakan [Trattamento della vasculopatie periferiche con una nuova sostanza estrattiva: il Tanakan]. Clinica Europea 1981;20:936-944
22. Horsch S, Holscher U. Infusion therapy with ginkgo biloba special extract EGb 761 in patients with PAOD fontaine stages III and IV - A reference- controlled double-blind clinical trial. Munchener Medizinische Wochenschrift 1998;140(16):232-236 (Pubitemid 28231922)
23. Li AL, Shi YD, Landsmann B, Schanowski-Bouvier P, Dikta G, Bauer U, et al. Hemorheology and walking of peripheral arterial occlusive diseases patients during treatment with Ginkgo biloba extract. Acta pharmacologica Sinica 1998;19(5):417-421 (Pubitemid 28423582)
24. Michelini S, Micci A, Failla A, Moneta G, Ottaviani A. Study on the efficiacy of ginkgo biloba extract, magnesium and levo-arginine in the treatment of patients with 2d stage arteriopathies. A preliminary study [Studio sull'efficiaca dell'estratto di ginkgo biloba, magnesio e levo-arginina nel trattamento dei pazienti arteriopatici al II stadio]. Minerva Cardioangiologica 1998;46(9):319-320
25. Rudofsky G. Effect of Ginkgo biloba extract in cases of arterial occlusive disease. Randomized placebo controlled crossover study. Fortschritte der Medizin 1987;105(20):397-400. (Pubitemid 17093587)
26. Schweizer J, Hautmann C. Comparison of two dosages of ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's stage IIb: A randomised, double-blind, multicentric clinical trial. Arzneimittel-Forschung 1999;49(11):900-904
27. Antithrombotic Trialist's Collaboration (ATC). Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. British Medical Journal 2002;324(7329):71-86. (Pubitemid 34073138)
28. Bauer U. Ginkgo biloba extract in the treatment of arteriopathy of the lower extremities. A 65 week trial. Presse Medicale 1986;15(31): 1546-1549 (Pubitemid 16018122)
29. Bauer U. A two-year study of ginkgo biloba extract in the treatment of peripheral arterial disease (Fontaine stage IIb). What is New in Angiology? Trends and Controversies. Zuckschwerdt, W, 1986:531-532
30. Bauer U. Long-term treatment of the peripheral arterial clasp illness with Ginkgo biloba extract (GBE); a 3-year-investigation [Langzeitbehandlung der peripheren arteriellen Verschlusskrankheit met Ginkgo biloba Extrakt (GBE); eine 3-Jahres-Untersuchung]. Vasa 1986;15:S26.
31. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Medical management of peripheral arterial disease. Journal of Thrombosis & Haemostasis 2005;3(8):1628-1637 (Pubitemid 41716548)
32. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database of Systematic Reviews 2006, Issue 2. [Art. No.: CD005263. DOI: 10.1002/14651858.CD005263.pub2]
33. de Backer TL, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD000988.pub3]
34. De Backer TLM, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD001368.pub3]
35. Fontaine R, Kim M, Kieny R. Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripheren Durchblutungsstörungen] . Helvetica Chirurgica Acta 1954;5/6:499-533.
36. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology 1991;20(2):384-392
37. Girolami B, Bernardi E, Prins MH, ten Cate JW, Hettiarachchi R, Prandoni P, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. A metaanalysis. Archives of Internal Medicine 1999;159(4):1955-1956
38. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006;295(5):547-553 (Pubitemid 43200349)
39. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. The Cochrane Collaboration, 2008.
40. Hooi JD, Stoffers HE, Kester AD, Rinkens PE, Kaiser V, van Ree JW, et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusion disease. The Limburg PAOD study. Peripheral Arterial Occlusive Disease. Scandinavian Journal of Primary Health Care 1998;16(3):177-182 (Pubitemid 28459675)
41. Horsch S, Walther C. Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD) - a review based on randomized, controlled studies. International Journal of Clinical Pharmacology and Therapeutics 2004;42(2):63-72. (Pubitemid 38219916)
42. Kleijnen J, Knipschild P. Ginkgo biloba. The Lancet 1992;340 (8828):1136-1139
43. Korth R, Nunez D, Bidault J, Benviste J. Comparison of three pafacether antagonist ginkgolides. European Journal of Pharmacology 1988;152(1-2):101-110 (Pubitemid 18187806)
44. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2004, Issue 1. [Art. No.: CD000990. DOI: 10.1002/14651858.CD000990]
45. Letzel H, Schoop W. Gingko biloba extract EGb 761 and pentoxifylline in intermittent claudication. Secondary analysis of the clinical effectiveness [Ginkgo-biloba-Extrakt EGb 761 und Pentoxifyllin bei Claudicatio intermittens. Sekundäranalyse zur klinischen Wirksamkeit]. VASA 1992;21(4):403-410
46. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the eldery: The Rotterdam Study. Arteriosclerosis, Thrombosis & Vascular Biology 1998;18(2):185-192 (Pubitemid 28277594)
47. Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 2000;59(5):1057-1070 (Pubitemid 30339130)
48. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. American Heart Journal 2002;143(6): 961-965 (Pubitemid 34666884)
49. Pincemail J, Dupuis M, Nasr C, Hans P, Haag-Berrurier M, Anton R, et al. Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia 1989;45(8):708-712 (Pubitemid 19198311)
50. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. The American journal of medicine 2000;108(4):276-281 (Pubitemid 30110455)
51. Robak J, Gryglewski RJ. Flavonoids are scavengers of superoxide anions. Biochemical Pharmacology 1988;37(5):837-841 (Pubitemid 18058453)
52. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database of Systematic Reviews 2008, Issue 1, CD003748. [DOI: 10.1002/14651858.CD003748.pub3]
53. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. [erratum appears in J Vasc Surg 2001 Apr;33(4):805]. Journal of Vascular Surgery 1997;26(3):517-538
54. Schneider B. Ginkgo biloba extract in peripheral arterial diseases. Meta-analysis of controlled clinical studies [Ginkgo-biloba-Extraxt bei peripheren arteriellen Verschlusskrankheiten; Meta-analyse von kontrolierten klinischen Studien]. Arzneimittel-Forschung 1992;42 (4):428-436